RS51526B - Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera - Google Patents

Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera

Info

Publication number
RS51526B
RS51526B RSP-2010/0547A RSP20100547A RS51526B RS 51526 B RS51526 B RS 51526B RS P20100547 A RSP20100547 A RS P20100547A RS 51526 B RS51526 B RS 51526B
Authority
RS
Serbia
Prior art keywords
ethyl
fluoro
imidazolidin
ylamino
benzo
Prior art date
Application number
RSP-2010/0547A
Other languages
English (en)
Serbian (sr)
Inventor
Hong-Yu Li
Harold Burns Brooks
Joyce Z. Crich
James Robert Henry
Jason Scott Sawyer
Yan Wang
Original Assignee
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & Company filed Critical Eli Lilly & Company
Publication of RS51526B publication Critical patent/RS51526B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
RSP-2010/0547A 2006-12-21 2007-12-11 Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera RS51526B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87132206P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
RS51526B true RS51526B (sr) 2011-06-30

Family

ID=39185681

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0547A RS51526B (sr) 2006-12-21 2007-12-11 Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera

Country Status (21)

Country Link
US (1) US8063212B2 (enExample)
EP (1) EP2125794B1 (enExample)
JP (1) JP2010513553A (enExample)
KR (1) KR101080594B1 (enExample)
CN (1) CN101568539B (enExample)
AT (1) ATE485291T1 (enExample)
AU (1) AU2007334040B2 (enExample)
BR (1) BRPI0720607A2 (enExample)
CA (1) CA2673564A1 (enExample)
CY (1) CY1110950T1 (enExample)
DE (1) DE602007010041D1 (enExample)
DK (1) DK2125794T3 (enExample)
EA (1) EA016178B1 (enExample)
ES (1) ES2351371T3 (enExample)
HR (1) HRP20100641T1 (enExample)
MX (1) MX2009006635A (enExample)
PL (1) PL2125794T3 (enExample)
PT (1) PT2125794E (enExample)
RS (1) RS51526B (enExample)
SI (1) SI2125794T1 (enExample)
WO (1) WO2008076705A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479680T1 (de) 2006-12-21 2010-09-15 Lilly Co Eli Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
TW200908981A (en) * 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
CN104781257A (zh) 2012-06-14 2015-07-15 第一三共株式会社 哌啶基吡唑并吡啶衍生物
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
KR102693614B1 (ko) 2022-04-04 2024-08-08 경희대학교 산학협력단 나프탈렌-2-일알킬기가 치환된 이미다졸리움 유도체 및 이를 유효성분으로 포함하는 암 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
WO2004063192A1 (en) 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
ATE479680T1 (de) 2006-12-21 2010-09-15 Lilly Co Eli Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds

Also Published As

Publication number Publication date
CN101568539B (zh) 2012-04-25
EP2125794A1 (en) 2009-12-02
MX2009006635A (es) 2009-06-30
PT2125794E (pt) 2011-01-10
CY1110950T1 (el) 2015-06-10
BRPI0720607A2 (pt) 2014-04-08
US20100081641A1 (en) 2010-04-01
ATE485291T1 (de) 2010-11-15
HRP20100641T1 (hr) 2010-12-31
SI2125794T1 (sl) 2011-02-28
KR20090086111A (ko) 2009-08-10
EP2125794B1 (en) 2010-10-20
DE602007010041D1 (de) 2010-12-02
CN101568539A (zh) 2009-10-28
JP2010513553A (ja) 2010-04-30
EA200970616A1 (ru) 2009-10-30
DK2125794T3 (da) 2011-01-24
AU2007334040A1 (en) 2008-06-26
KR101080594B1 (ko) 2011-11-04
AU2007334040B2 (en) 2012-02-16
ES2351371T3 (es) 2011-02-03
EA016178B1 (ru) 2012-02-28
US8063212B2 (en) 2011-11-22
CA2673564A1 (en) 2008-06-26
PL2125794T3 (pl) 2011-04-29
WO2008076705A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
KR101131261B1 (ko) 트리아졸릴 아미노피리미딘 화합물
RS51526B (sr) Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera
AU2008254318B2 (en) Triazolyl aminopyrimidine compounds
JP5166441B2 (ja) 癌治療用イミダゾリジノニルアミノピリミジン化合物